Categories Earnings, Health Care
Johnson & Johnson (JNJ) beats Q4 earnings estimates, misses on revenue
Johnson & Johnson (NYSE: JNJ) topped earnings estimates for the fourth quarter of 2019 while revenues fell short of expectations. The shares were down 1.5% in premarket hours on Wednesday.
Total revenue of $20.7 billion inched up 1.7% from the same period last year, but came slightly below consensus forecasts of $20.8 billion. Adjusted operational sales, which excludes impacts from acquisitions, divestitures and currency translations, increased 3.4%.
GAAP net income grew 31.8% to $4 billion and EPS improved around 34% to $1.50. Adjusted net income fell 6.4% year-over-year to $5 billion. Adjusted EPS dropped 4.6% to $1.88 but beat estimates of $1.87.
Alex Gorsky, Chairman and CEO stated, “We delivered strong underlying sales and earnings growth in 2019, driven by the strength of our Pharmaceutical business, accelerating performance in our Medical Devices business and improved profitability in our Consumer business.”
Sales in the US increased 1.4% to $10.7 billion while international sales rose 2.1% to $9.9 billion. The Consumer and Pharmaceutical segments saw sales increases of 0.9% and 3.5% respectively, while sales in the Medical Devices segment was down 0.5%.
For the full year of 2020, the company expects reported sales to grow 4-5% to $85.4 billion to $86.2 billion. Operational sales are expected to grow 4.5-5.5% to $85.8-$86.6 billion. Adjusted operational sales are expected to grow 5-6%.
Adjusted EPS is expected to increase 3.1-4.8% to a range of $8.95-9.10 and adjusted operational EPS is expected to rise 3.7-5.4% to a range of $9.00-9.15.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on